Characteristic | n (%) |
---|---|
Age (years, median, IQR) | 75.5, 63.5–81.7 |
Male sex | 27 (75) |
Underlying disease | |
Immunosuppressiona | 9 (25) |
Diabetes mellitus | 18 (50) |
Chronic obstructive lung disease | 5 (13.9) |
Cerebral vascular disease | 10 (27.8) |
Chronic kidney disease, stage = 4 or 5 | 13 (36.1) |
Hemodialysis | 11 (30.6) |
Malignancy | 14 (38.9) |
Hematological malignancy | 3 ( 8.3) |
Solid tumor | 11 (30.6) |
Liver cirrhosis | 3 (8.3) |
Charlson comorbidity score (median, IQR) | 3, 2–6 |
Community-acquired infections | 3 ( 8.3) |
Healthcare-associated infectionsb | 6 (16.7) |
Nosocomial infectionsb | 27 (75) |
ICU | 14 (38.9) |
Medical ward | 8 (22.2) |
Surgical ward | 5 (13.9) |
Polymicrobial infection | 2 (5.6) |
Antibiotic exposure in the past 30 days, ≥3 days | |
Any | 29 (80.6) |
Tigecycline | 13 (36.1) |
Glycopeptides | 11 (30.6) |
β-lactams plus β-lactamase inhibitors | 12 (33.3) |
First- and second-generation cephalosporins | 11 (30.6) |
Third- or fourth-generation cephalosporins | 10 (27.8) |
Carbapenem | 9 (25) |
Fluoroquinolones | 8 (22.2) |
Metronidazole | 9 (25) |
Ward, duration of stay and devices at the time of bacteremia | |
Acquired after ICU >48 h | 14 (38.9) |
Days of hospitalization before bacteremia (median, IQR) | 48, 18–82 |
Urinary catheter | 17 (47.2) |
Central venous catheter | 23 (63.9) |
Mechanical ventilation | 18 (50) |
Pitt bacteremia score (mean ± SD) | 4 ± 4 |
APACHE II score (mean ± SD) | 23 ± 10 |
Infection sources and clinical syndrome | |
Pneumonia | 10 (27.8) |
Intra-abdominal infection other than biliary-tract infection | 5 (13.9) |
Biliary-tract infection | 7 (19.4) |
Skin and soft-tissue infection | 2 (5.6) |
Catheter infection | 1 (2.8) |
Urinary-tract infection | 1 (2.8) |
Unknown primary focus | 10 (27.8) |
Appropriate antibiotic treatment | 17 (47.2) |
Outcome | |
Presentation with septic shock | 19 (52.8) |
Requiring admission to ICU after bacteremia | 19 (52.8) |
In-hospital death | 17 (47.2) |
28-day mortality | 14 (38.9) |